Endoglycosidase
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Endoglycosidase
Endoglycosidase drugs function by cleaving glycosidic bonds within complex carbohydrates, most notably hyaluronic acid, a major component of the extracellular matrix. This enzymatic action temporarily disperses the matrix, increasing tissue permeability and facilitating the subcutaneous or intramuscular delivery of co-administered therapeutics, such as monoclonal antibodies. This mechanism enhances drug absorption and distribution, allowing for less frequent dosing and improved patient convenience. The first approved drugs utilizing this mechanism were AMPHADASE and HYLENEX RECOMBINANT, both hyaluronidases, approved in 2004 and 2005 respectively, primarily for dehydration and as an excipient to increase the absorption of other drugs. The field has since evolved significantly, with hyaluronidase now routinely incorporated into subcutaneous formulations of biologics.
This class of drugs has expanded beyond simple excipient use to become integral components of novel drug delivery systems for a range of indications. Approved drugs now include RITUXAN HYCELA for follicular lymphoma and diffuse large B-cell lymphoma, HERCEPTIN HYLECTA and PHESGO for breast cancer, DARZALEX FASPRO for multiple myeloma, VYVGART HYTRULO for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, TECENTRIQ HYBREZA for non-small cell lung cancer, and OCREVUS ZUNOVO for multiple sclerosis. The trend is towards combining endoglycosidases with potent biologics to enable subcutaneous administration, thereby improving patient compliance and potentially reducing healthcare costs associated with intravenous infusions. The future trajectory points towards further integration of endoglycosidase technology across various therapeutic areas, optimizing the delivery of complex biologics.
The clinical utility of endoglycosidases is primarily as a delivery enhancer for large molecule therapeutics, enabling subcutaneous administration. This has revolutionized the treatment landscape for chronic conditions and oncology, offering patients more convenient dosing options. The success of drugs like DARZALEX FASPRO and RITUXAN HYCELA highlights the significant patient benefit derived from transitioning from intravenous to subcutaneous delivery. As the technology matures, we anticipate broader adoption across different biologic modalities and therapeutic areas, further solidifying the role of endoglycosidases in modern pharmacotherapy. The ongoing research and development efforts are focused on refining delivery systems and expanding the range of biologics that can leverage this enzymatic enhancement for improved patient outcomes and healthcare system efficiency.
12 FDA-approved Endoglycosidase drugs, including AMPHADASE, with 422 active Phase 3 trials across 8 indications from 10 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Endoglycosidase Drugs
12 totalEndoglycosidase drugs, primarily hyaluronidases, first emerged as standalone agents like AMPHADASE (2004) and HYLENEX RECOMBINANT (2005) to facilitate fluid absorption and dispersion. Their evolution into sophisticated drug delivery enhancers began with their incorporation into subcutaneous formulations of biologics. Early next-generation products focused on improving the purity and recombinant production of hyaluronidase, leading to enhanced safety profiles and broader applicability. Subsequent advancements involved pairing these enzymes with increasingly complex biologics, such as monoclonal antibodies, to enable convenient subcutaneous administration, a significant improvement over traditional intravenous infusions. This evolution has transformed the delivery of treatments for chronic and oncologic conditions. Individual drugs within the endoglycosidase class differentiate primarily through the biologic they are paired with and the specific indications they target. For instance, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) offers a subcutaneous option for multiple myeloma, contrasting with the intravenous formulation of its predecessor. Similarly, HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) and PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) provide subcutaneous alternatives for breast cancer treatment, reducing infusion times. VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) enables subcutaneous delivery for myasthenia gravis and CIDP. These combinations offer distinct advantages in terms of dosing frequency, administration time, and patient convenience compared to their IV counterparts. Today, endoglycosidase-enhanced drugs are established standards of care in their respective therapeutic areas, particularly for chronic conditions and oncology where frequent IV infusions were previously required. They are often utilized in first-line or subsequent treatment settings, offering significant benefits in patient compliance and quality of life. While biosimilar competition for the biologic component is emerging, the hyaluronidase excipient itself is generally proprietary to the originator's formulation. Class-wide safety dynamics are largely tied to the co-administered biologic, with the hyaluronidase component generally well-tolerated, contributing to the overall positive clinical positioning of these subcutaneous formulations.
Endoglycosidase Indications in Trials
Active industry trialsEndoglycosidase activity is currently most concentrated in Non-Small Cell Lung Cancer, with 26 active trials, followed closely by Advanced Solid Tumor (22 active trials) and Melanoma (20 active trials). Significant activity is also seen in Advanced Solid Tumors (14 active trials) and Carcinoma, Non-Small-Cell Lung (14 active trials), indicating a strong focus on major oncologic indications. The substantial number of trials in these areas suggests a continued effort to leverage endoglycosidase technology for improving the delivery and efficacy of cancer therapeutics, particularly for biologics administered subcutaneously. The pipeline is expanding beyond the initial indications, with novel patient subpopulations and combination regimens being explored. While the provided data highlights established oncology indications, the underlying trend of enabling subcutaneous delivery for biologics suggests potential exploration in autoimmune diseases, rare genetic disorders, and other areas where biologics are used. The modality trend is overwhelmingly towards injectable subcutaneous formulations, enhancing patient convenience. Sponsors are actively investigating combinations of endoglycosidase-enhanced biologics with other therapeutic agents to achieve synergistic effects or overcome resistance mechanisms, pushing the boundaries of current treatment paradigms. In the next 6-12 months, key readouts are expected from ongoing Phase 2 and Phase 3 trials in Non-Small Cell Lung Cancer, Advanced Solid Tumors, and Melanoma. These results will be crucial in determining the future expansion of endoglycosidase-enabled therapies in oncology. Bottleneck disease subsets where the class has yet to demonstrate significant impact may emerge as areas for future research. Signals suggesting a rich pipeline include the consistent investment by major sponsors and the expansion into new therapeutic areas. Conversely, thinning pipeline activity in certain indications or a lack of novel biologic pairings could indicate saturation or challenges in further leveraging this technology.
Top Endoglycosidase Sponsors
Industry trials, any indicationMerck Sharp & Dohme LLC leads endoglycosidase-related activity with 83 active trials, likely driven by the extensive development and application of KEYTRUDA QLEX (pembrolizumab) and its subcutaneous formulation. This dominance stems from Merck's deep franchise in immuno-oncology, where KEYTRUDA is a cornerstone therapy across numerous indications, and the strategic decision to develop a subcutaneous version to enhance patient access and convenience. Their broad pipeline reach, encompassing multiple indications and trial phases, solidifies their leading position in leveraging this delivery technology. Key challengers include Bristol-Myers Squibb with 29 active trials and AstraZeneca with 22 active trials. Bristol-Myers Squibb is actively involved with OPDIVO QVANTIG (nivolumab), another significant immuno-oncology agent, suggesting a similar strategy to Merck in developing subcutaneous options. AstraZeneca's activity, while not tied to a specific named drug in the provided list, indicates a broader interest in endoglycosidase technology for their biologic portfolio. Hoffmann-La Roche follows with 19 active trials, building on its established portfolio of biologics like RITUXAN HYCELA, HERCEPTIN HYLECTA, PHESGO, and OCREVUS ZUNOVO, demonstrating a sustained commitment to subcutaneous delivery. The strategic landscape for endoglycosidase sponsors is characterized by a strong focus on oncology, particularly Non-Small Cell Lung Cancer and Melanoma, as indicated by the high trial counts. Merck and Bristol-Myers Squibb are aggressively pursuing market share in these indications with their subcutaneous immuno-oncology agents. Hoffmann-La Roche continues to expand its range of subcutaneous biologics across various therapeutic areas. Upcoming catalysts include Phase 3 trial readouts and potential new drug approvals, which could significantly shift the competitive balance. For investors and BD scouts, the key is to identify sponsors with robust biologic pipelines that can benefit from subcutaneous formulation, as well as those developing novel endoglycosidase technologies or exploring new therapeutic applications.
Endoglycosidase Phase 3 Readout Calendar Pro
12 Phase 3 trials testing approved Endoglycosidase drugs across 12 indications from 8 sponsors. Earliest readout: Q2 2024.
Coverage: trials whose intervention is an approved Endoglycosidase drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.